Volume Buzz: Novogen Limited, AMR Corporation, Netflix, Inc., Pluristem Therapeutics Inc

Lakeway, TX -- (SBWIRE) -- 02/21/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Novogen Limited (ADR) (NASDAQ:NVGN) among the gainers and the stock augmented 18.16% to $9.63. The 52-week range for the stock is $0.48 and $9.70. The Company has Price/Sales ratio of 21.68 and Price/Book ratio of 9.59. The 50-Day Moving Average and 200-Day Moving Average prices is $2.40 and $1.52 respectively. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing.

How Should Investors Trade NVGN After The Recent Movement? Find Out Here

AMR Corporation (PINK:AAMRQ) soared 9.16% to $2.74. JPMorgan re-initiated AMR Corp. with an overweight rating.

Moody's Investors Service said that the merger of American Airlines and U.S. Airways to form the world's largest air carrier threatens the credit quality of U.S. airports as the combined airline may eliminate routes or push up ticket prices.

Is AAMRQ Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Netflix, Inc. (NASDAQ:NFLX) went up 1.10% to $189.18. The Company disrupts the television world. Netflix also changed the rules in how they presented the series. In breaking with the traditional scheduled show times, Netflix released the entire series at once- all thirteen episodes. Binge viewing and social media support groups sprung up across the internet on the weekend of its release. Netflix incorporated on August 29, 1997, is an Internet subscription service streaming television shows and movies.

Is NFLX a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Pluristem Therapeutics Inc. (NASDAQ:PSTI) moved up 2.40% to $3.41. The Company announced that the U.S. Food and Drug Administration have designated Pluristem's PLacental expanded cells orphan drug status for the treatment of aplastic anemia.

How Should Investors Trade PSTI After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.